Xintela AB Interim report January – September 2021
Xintela AB Interim report January – September 2021 Summary of the interim report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Third quarter July 1 – September 30, 2021 Income amounted to TSEK 0 (0). Loss before tax totalled TSEK 10,910 (loss: 8,315). Loss per share* was SEK 0.13 (loss: […]
Update on status and strategy for Xintela and Targinta
Xintela develops stem cell-based treatments with a focus on osteoarthritis and difficult-to-heal leg ulcers and, through its wholly owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers. We are focused on diseases where there is a high medical need and where effective treatments are lacking today. Solid preclinical R&D has laid the foundation for Xintela’s […]
New board of directors appointed in Targinta AB
Xintela AB announces the appointment of a new board of directors in Targinta AB, a wholly-owned subsidiary of Xintela. Jeffrey Abbey, Karin Wingstrand and Maarten de Château have been appointed as new board members. Gregory Batcheller, chairman, and Evy Lundgren-Åkerlund are already members of the board of Targinta. Gunnar Telhammar resigns as board member. The […]
Xintela taking EQSTEM, a stem cell product for horses, towards the market
In a recently completed study in horses, the stem cell product EQSTEM® shows significantly reduced lameness in horses with osteoarthritis (OA) due to joint injury, indicating that this product can reduce joint pain and improve joint function. Xintela is now taking EQSTEM further to the animal health market and will, in dialogue with EMA (European […]
Targinta selects lead drug candidate for triple-negative breast cancer
The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin a10b1. TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triple-negative breast cancer models. Xintela, of which Targinta is a wholly […]
Xintela to expand clinical development of stem cell product XSTEM
Lund, Sweden, September 30 2021 – Xintela announces it will expand clinical development of its stem cell product XSTEM to the next chosen indication venous leg ulcers, the most common type of difficult-to-heal (chronic) wounds in humans. A scientific advice meeting with the Swedish Medical Products Agency (MPA) has been successfully completed and preparation of […]
Xintela Half-year Report 2021-01-01 – 2021-06-30
Summary of the half-year report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Second quarter 1 April – 30 June 2021 · Income amounted to TSEK 0 (0). · Loss before tax totalled TSEK 11,797 (loss: 9,087). · Loss per share* was SEK 0.13 (loss: 0.22). · At 30 June […]
Closing in on our next major milestone
Closer to clinical trials We are now closing in on our next major milestone: initiating clinical trials with the stem cell product XSTEM. Many pieces of the puzzle have fallen into place for us to get this far, each of which reflects a great deal of hard, goal-oriented work by our team. Some of […]
Xintela signs with Australian CRO for clinical study
Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO) to conduct Xintela’s First-in-Human study using the stem cell product XSTEM. Xintela’s First-in-Human study with the stem cell product XSTEM, a combined phase I/II clinical study on patients with knee osteoarthritis, will be conducted in Australia […]
Xintela incorporates subsidiary in Australia
Xintela has formed a wholly owned subsidiary, Xindu Pty Ltd, in Australia, which will administer the company’s upcoming clinical study on osteoarthritis patients. Xintela has previously announced that the company is planning a clinical study (Phase I / IIa) in Australia where the stem cell product XSTEM® will be tested for the treatment of osteoarthritis. […]
